Humacyte Inc
NASDAQ:HUMA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.96
4.72
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Humacyte Inc
Humacyte, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. The company is headquartered in Durham, North Carolina and currently employs 145 full-time employees. The company went IPO on 2020-09-22. The company is developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The firm has developed a paradigm for manufacturing human tissues that is intended to mimic key aspects of human physiology. The company is developing and manufacturing acellular tissues to address life- and limb-threatening vascular conditions while focusing on potential future applications for complex tissue and organ diseases. The company is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes.
Humacyte, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. The company is headquartered in Durham, North Carolina and currently employs 145 full-time employees. The company went IPO on 2020-09-22. The company is developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The firm has developed a paradigm for manufacturing human tissues that is intended to mimic key aspects of human physiology. The company is developing and manufacturing acellular tissues to address life- and limb-threatening vascular conditions while focusing on potential future applications for complex tissue and organ diseases. The company is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes.
Revenue Growth: Revenue for Q3 2025 was $0.8 million, up from $0 in the prior year period, driven by a significant increase in Symvess product sales following its commercial launch.
Commercial Traction: Symvess is now approved for purchase in 92 civilian hospitals, with 45 additional VAC committees reviewing it. Sales and reorders are increasing, and the majority of initial customers have reordered.
Clinical Evidence: Multiple newly published studies show strong long-term outcomes for Symvess in vascular trauma, supporting its adoption among surgeons and hospitals.
Dialysis Access Progress: Positive 2-year results for Symvess in dialysis access patients were presented, with plans for a supplemental BLA filing in the second half of 2026, pending interim trial results.
Cost Control: Operating expenses, especially R&D, fell significantly quarter-over-quarter, with management reaffirming their $50 million cost-saving target.
Cash Position: Cash and equivalents were $19.8 million at quarter-end, with an additional $56.5 million raised after the quarter, providing a cash runway exceeding 12 months and covering key milestones.
Price Strategy: Lowering the price of Symvess has accelerated hospital adoption and speeded up the approval process at hospitals.
